Nicotinamide mononucleotide (NMN)
Nicotinamide mononucleotide (NMN) is a precursor of the coenzyme Nicotinamide adenine dinucleotide (NAD+), which serves critical functions in our cells and declines with age. NMN supplementation may counteract the effects of CD38, which is secreted by senescent cells. NAD+ biology has seen a great deal of interest in the last few years, partially due to the discovery of two precursors of NAD+ biosynthesis, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which both increase NAD+ in multiple tissues.
Accumulating evidence suggests that NAD+ systemically declines with age in a variety of organisms, including rodents and humans, which contributes to the development of many age-related diseases. For this reason, there is a great deal of interest in creating potential interventions that increase NAD+ levels via precursors, thus delaying or even preventing certain aspects of age-related functional decline and diseases.
For those interested in exploring the complex and fascinating world of Nicotinamide mononucleotide and its role in aging biology we have written an introductionary two-part series called NAD World.